Showing promise in the arena of obesity treatment, retatrutide presents a different strategy. Unlike many current medications, retatrutide functions as a dual agonist, simultaneously targeting both GLP peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) sensors. This dual stimulation fosters various helpful effects, including e